Proteins & antibodies

Our recombinant protein and antibody capabilities include mammalian cell line generation, production, purification and analysis of recombinant proteins and antibodies manufactured in mammalian systems.

Protein and antibody capabilities

Here at Batavia Biosciences, we generate protein and antibody products as well as perform process development and scale-up of such products in our Woburn facility (MA, USA). Clinical manufacturing of all products is performed in our GMP facility located in the Netherlands. Batavia Biosciences offers unique technologies to increase protein and antibody product yields, decrease process development time, and improve product stability. In general, our strengths include vector construction, stable mammalian cell line generation, small- and large-scale transient production, upstream and downstream process development and scale-up, medium selection, feed strategy optimization, analytical development, product characterization and cGMP manufacturing. Our comprehensive expertise allows us to deliver a complete package comprising of purified product together with all relevant protocols and pivotal biochemical and analytical characterization data.

Proteins and antibodies track record

We have successfully delivered a diverse range of biosimilars including growth factors, fertility hormones, enzymes, anti-cancer fusion proteins, clotting factors, antibodies, antibody fragments, viral proteins and antigenic proteins. For instance, in collaboration with Prof. James Crowe (Pediatrics & Pathology, Microbiology & Immunology Department, Vanderbilt Vaccine Center, Nashville) we have worked on the generation of CHO cell lines expressing potent virus-neutralizing antibodies. Additionally, for COPro Biotech, we have used our STEP® technology to develop a stable biosimilar producer cell line.

The proactive thinking and problem-solving mindset at Batavia have been very much appreciated. Getting our potent antibodies from bench to clinic is an absolute priority.

Prof. James CroweVanderbilt Vaccine Center

With pleasure we have collaborated with the Batavia team on cell line development. Their STEP® technology is very suitable for generating biosimilar producing cell lines.

Yiding WangDirector Operations, COPro Biotech

Proteins & antibodies technologies

STEP® technology

To enable the rapid generation of stable protein or antibody expressing CHO cell lines, we have developed an affordable and complete package of services and technologies. Our approach provides significant more product per cell compared to commercially available benchmarks.

Learn more

SCOUT® technology

SCOUT® technology is an effective tool for Design-of-Experiments (DoE) approaches as it uses a miniaturized production and purification platform to quickly develop multivariate processes.

Learn more

Process development

We develop scalable, robust and GMP-compliant manufacturing processes for viral vectors.

Upstream process development

We deliver scalable and robust GMP-compliant purification processes for recombinant proteins.

Learn more

Downstream process development

We deliver scalable and robust GMP-compliant purification processes for recombinant proteins.

Learn more

Analytical development

We support the development of all the required product-specific release and stability-determining assays for your recombinant protein.

Learn more

In silico cost modeling

We often perform in silico cost modeling of manufacturing processes for recombinant protein products.

Learn more

Related resources

How important is matrix effect in analyzing bioprocess samples?

| Blog, Proteins antibodies | No Comments
Written by expert: Gert, Associate Director Assays The matrix effect is the effect on an analytical assay caused by all other components of the sample except the specific compound (analyte)…
Cell line development for difficult to express proteins

Developing stable cell lines for difficult to express proteins: laronidase example

| Blog, Proteins antibodies | No Comments
Written by expert: Wilfried, Director of Science and Innovation For protein-based biopharmaceuticals, product yield from mammalian cell lines is a critical economic driver. Naturally, increased specific productivity – microgram product…
protein expressing cell line

Improved selection of protein-producing cell lines using a scale-down approach – a case study

| Blog, Proteins antibodies | No Comments
Written by expert: Alfred, Global Technical Sales Director The selection of stable protein producing cell lines is tedious, time consuming and capital intensive. The introduction of various high-throughput cell screening…
increase production yield

The need to increase production yield of therapeutic proteins

| Blog, Proteins antibodies | No Comments
Written by Expert: Wilfried, Director Science & Innovation. Biopharmaceuticals are expensive due to the many years of research and development associated with the discovery, development, clinical testing, and market launch…
Process development

Talk to our experts

Remco Spanjaard - Bioprocess expert
Remco Spanjaard

Technical Lead
+31 (0) 88 9950600

Send us a message